Related Experiment Video
Updated: Mar 18, 2026

Experimental Protocol of a Three-minute, All-out Arm Crank Exercise Test in Spinal-cord Injured and Able-bodied Individuals
Published on: June 8, 2017
A Tale of 3 Trials: ACCORD, SPRINT, and SPS3. What Happened?
1Department of Medicine/Cardiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Lawrence.krakoff@mountsinai.org.
Insights
Lowering blood pressure goals in hypertension treatment may prevent cardiovascular disease. A meta-analysis suggests a systolic pressure of 125-135 mm Hg is optimal for most patients.
Area of Science:
- Cardiology
- Clinical Trials
- Hypertension Research
Background:
- The National Institutes of Health funded three major randomized clinical trials (ACORD, SPRINT, SPS3) to evaluate lower blood pressure targets for cardiovascular disease and stroke prevention.
- These trials collectively involved 17,114 participants and aimed to determine if reduced systolic blood pressure goals offer greater benefits.
Purpose of the Study:
- To assess the efficacy of intensive blood pressure lowering treatment versus standard treatment in preventing cardiovascular events.
- To compare the outcomes of three distinct randomized clinical trials with varying inclusion criteria and target blood pressures.
Main Methods:
- Three large-scale randomized clinical trials (ACORD, SPRINT, SPS3) were conducted.
- Participants were assigned to either intensive blood pressure treatment (lower goal) or standard treatment.
- Primary outcomes related to cardiovascular disease and stroke prevention were analyzed.
Main Results:
- The SPRINT trial demonstrated a significant reduction in primary outcomes with intensive treatment.
- The ACCORD and SPS3 trials did not show statistically significant benefits for their primary outcomes.
- Subgroup analyses revealed both similarities and differences across the trials.
Conclusions:
- When considered collectively with observational studies, these trials suggest an optimal systolic blood pressure range of 125-135 mm Hg for most hypertensive patients on treatment.
- Intensive blood pressure management may offer significant benefits for specific patient populations, as indicated by the SPRINT trial results.
Abstract:
Within the last several years, the National Institutes of Health has supported three randomized clinical trials to determine whether lower than usually recommended goals for treatment of hypertension would have greater benefit for prevention of cardiovascular disease and stroke. These were the ACCCORD, SPRINT, and Secondary Prevention of Small Subcortical Strokes (SPS3) Trials. Together they enrolled 17,114 participants. Results for all three have been reported. The trials differ from each other in their inclusion criteria, target blood pressures for the lower goal (intensive treatment), but are similar in many respects. The results with regard to their primary outcome were different: not significant for ACCORD and SPS3, but definitely significant for SPRINT. Subgroup analysis revealed differences and similarities. When viewed together and with recent large observational studies, they support a conclusion that a systolic pressure in the range of 125-135 mm Hg range is likely to be optimal on treatment for most hypertensive patients.
Related Concept Videos
Torts III
Quasi-intentional torts in healthcare involve acts where intent is not directed to harm an individual but results in harm due to careless or reckless speech.
Torque
Torque can be considered as the rotational counterpart to force. Since forces change the translational...
Torque Free Motion
Trial and Error and Algorithm
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
The Spindle Assembly Checkpoint

